Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06761703 · ClinicalTrials.gov registry record
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
A clinical trial, sponsored by Amgen.
- Completed
- Registry status
- 200
- Enrollment target
NCT06761703: Completed study, sponsored by Amgen.
NCT06761703 is a clinical trial that has completed, run by Amgen. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06761703 has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research and at home self-blood testing. This study will engage an active community of people using anti-obesity medications, semaglutide and tirzepatide, indicated for weight loss to examine the willingness of participants to engage in a digital study, provide consent, and complete various study-related tasks, including a self-collected capillary blood sample for assay testing and health related surveys.
Interventions
- DEVICE TAP® Micro Select Device (Touch Activated Phlebotomy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-11-14 |
| Est. Completion | 2025-01-06 |
What the finished NCT06761703 record still lists
NCT06761703 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which TAP® Micro Select Device (Touch Activated Phlebotomy) is the first listed.
NCT06761703 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06761703 about?
NCT06761703 is a clinical study titled "A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss". This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research and at home self-blood testing. This study will engage an active commu...
What is the current status of trial NCT06761703?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2024-11-14. Estimated completion is 2025-01-06.
What interventions are being tested in trial NCT06761703?
The interventions under investigation include: TAP® Micro Select Device (Touch Activated Phlebotomy) (DEVICE).
Who is sponsoring clinical trial NCT06761703?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI